VivoSeq
2

Pipeline Programs

2

Active Trials

0

Companies Involved

Melasma is an early-stage landscape with 2 programs across 0 companies. 2 therapies are approved.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status2 · 20%
Recruiting1 · 10%
Active, not recruiting1 · 10%

Trial Activity

10 trials

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
Completed··N/A·NCT03878433·40 enrolled
Curcuma Xanthorriza Roxb. 10% Cream for Melasma
Unknown status·UUniversitas Padjadjaran·Phase 1·NCT06153134·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)